These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 28482702)

  • 1. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
    Buske C; Ogura M; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab biosimilars for lymphoma in Europe.
    Jurczak W; Długosz Danecka M; Buske C
    Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
    [No Abstract]   [Full Text] [Related]  

  • 5. Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.
    Kim WS; Ogura M; Kwon HC; Choi D
    Future Oncol; 2017 May; 13(15s):17-29. PubMed ID: 28482701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
    Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
    Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
    Rioufol C; Salles G
    Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT-P10 (Truxima™): A Rituximab Biosimilar.
    Deeks ED
    BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
    Jacobs I; Ewesuedo R; Lula S; Zacharchuk C
    BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory considerations in oncologic biosimilar drug development.
    Macdonald JC; Hartman H; Jacobs IA
    MAbs; 2015; 7(4):653-61. PubMed ID: 25961747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab biosimilars.
    Vital EM; Kay J; Emery P
    Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
    Coiffier B
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars are coming: ready or not.
    Zalcberg J
    Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U; Hong S; Oh C; Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.